Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: A phase II study

Annals of Oncology

Volumn 19, Issue 11, 2008, Pages 1903-1909

  Villalona Calero, Miguel A ^a,b   Otterson, G A ^a,b   Wientjes, M G ^a,b   Weber, F ^c   Bekaii Saab, T ^a,b   Young, D ^a,b   Murgo, A J ^a,b   Jensen, R ^a,b   Yeh, T K ^a,b   Wei, Y ^a,b   Zhang, Y ^a,b   Eng, C ^c   Grever, M ^a,b   Au, J L S ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Chemosensitization; Drug resistance; FGF; Lung cancer; Suramin

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; PACLITAXEL; SURAMIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER PATIENT; CANCER SURVIVOR; CHEMOSENSITIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FATIGUE; FEMALE; GENE MUTATION; HEARING LOSS; HUMAN; HYPERBILIRUBINEMIA; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG THROMBOSIS; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TINNITUS; TRANSAMINITIS; VEIN THROMBOSIS; VOMITING;

EID: 54949146895     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn412     Document Type: Article

References (58)

1. Taylor GW, Lui R, Fanta P et al. Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst 1992; 84: 489-494.
2. Frommel TO. Suramin is synergistic with vinblastine in human colonic tumor cell lines: Effect of cell density and timing of drug delivery. Anticancer Res 1997; 17: 2065-2071.
3. De Clercq E. Suramin: A patent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett 1979; 8: 9-22.
4. Calcaterra NB, Vicario LR, Roved OA. Inhibition by suramin of mitochondrial ATP synthesis. Biochem Pharmacol 1988; 37: 2521-2527.
5. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985; 29: 265-273.
6. Coffey RJ Jr., Leof EB, Shipley GD. Moses HL. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 1987; 132: 143-148.
7. Fujiuchi S, Ohsaki Y, Kikuchi K. Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor, Onoology 1997; 54: 134-140.
8. Waltenberger J, Mayr U, Frank H et al. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 1996; 28: 1523-1529.
9. Wade TP, Kasid A, Stein CA et al. Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. J Surg Res 1992; 53: 195-198.
10. Pollak M, Richard M. Suramin blockade of insulin like growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 1990; 82: 1349-1352.
11. Pesenti E, Sola F, Mongelli N et al. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992; 66: 367-372.
12. Khaled Z, Rideout D, O'Driscoll KR et al. Effects of suramin-related and other clinically therapeutic polyanions on protein Idnase C activity. Clin Cancer Res 1995; 1: 113-122.
13. La Rocca RV, Meer J, Gilliatt RW et al. Suramin-induced polyneuropathy. Neurology 1990; 40: 954-960.
14. Kobayashi K, Weiss RE, Vogelzang NJ et al. Mineralocorticoid insufficiency due to suramin therapy. Cancer 1996; 78: 2411-2420.
15. Katz SK, Medenica MM, Kobayashi K et al. Erythema multiforme induced by suramin. J Am Acad Dermatol 1995; 32: 292-293.
16. Kobayashi K, Pezen DS. Vogelzang NJ et al. Keratoacanthomas and skin neoplasms associated with suramin therapy. Arch Dermatol 1996; 132: 96-98.
17. Holland EJ, Stein CA, Palestine AG et al. Suramin keratapathy. Am J Ophthalmol 1988; 106: 216-220.
18. May E, Allolio B. Fatal toxic epidermal necrolysis during suramin therapy. Eur J Cancer 1991; 27: 1338.
19. Home MK 3rd, Wilson OJ, Cooper M et al. The effect of suramin on laboratory tests of coagulation. Thromb Haemost 1992; 67: 434-439.
20. Arlt W, Reincke M, Siekmann L et al. Suramin in adrenocortical cancer: limited efficacy and serious toxicity. Clin Endocrinol (Oxf) 1994; 41: 299-307.
21. Figg WD, Cooper MR, Thibault A et al. Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer 1994;.74: 1612-1614.
22. Stein CA, LaRocca RV, Thomas R et al. Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 1989; 7: 499-508.
23. Bitton RJ, Figg WD, Venzon DJ et al. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Onool 1995; 13: 2223-2229.
24. Chaudhry V, Eisenberger MA, Sinibaldi VJ et al. A prospective study of suramin-induced peripheral neuropathy. Brain 1996; 119: 2039-2052.
25. Danesi R, Del Bianchi S, Soldani P at al. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 1993; 68: 932-938.
26. Song S, Wientjes MG, Gan Y et al. Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000; 97: 8658-8663.
27. Zhang Y, Song S, Yang F et al. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 2G01; 299: 426-433.
28. Song S, Wientjes MG, Walsh C et al. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res 2001; 61: 6145-6150.
29. Xin Y, Grecula JC, Gupta N et al. Pharmacodynamics of the chemosensitizer suramin in radiotherapy. Proc Am Assoc Cancer Res 2006; 47: 138 (Abstr 582).
30. Tran J, Master Z, Yu JL et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99: 4349-4354.
31. Villalona-Calero MA, Wientjes MG, Otterson GA et al. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003; 15(9): 3303-3311.
32. Foekens JA, Sieuwerts AM, Stuurman-Smeets EM et al. Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro. Br J Cancer 1993; 67: 232-236.
33. Schrell UM, Gauer S, Kiesewetter F et al. Inhibition of proliferation of human cerebral meningioma cells by suramin: Effect on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. J Neurosurg 1995; 82: 600-607.
34. Trott A, Byhardt R, Stetz J et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
35. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States: National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
36. Kassack M, Nickel P. Rapid, highly sensitive gradient narrow-bore high-performance liquid chromatographic determination of suramin and its analogues. J Chromatogr B Biomed Appl 1996; 686: 275-284.
37. Hainsworth JD, Urba WJ, Hon JK et al. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. Eur J Cancer 1998; 34: 654-658.
38. Langer CJ, McAleer CA, Bonjo CA et al. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC). Eur J Cancer 2000; 3: 183-193.
39. Lynch T, Raju R, Lind M et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report. Proc Am Soc Clin Oncol 2003; 22: 623.
40. Sandler A, Gray R, Perry M et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
41. Johnson D, Fehrenbacher L, Novotny W et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
42. Ohta T, Yamamoto M, Numata M et al. Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br J Cancer 1995; 72: 824-831.
43. Volm M, Koomagi R, Mattern J, Stammler G, Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer 1997; 33: 691-693.
44. Faridi A, Rudlowski C, Bjesterfeld S et al. Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol Res Pract 2002; 198: 1-5.
45. Blanckaert VD, Hebbar M, Louchez MM et al. Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin Cancer Res 1998; 4: 2939-2947.
46. Colomer R, Aparicio J, Montero S et al. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 1997; 76: 1215-1220.
47. Linderholm BK, Lindh B, Beckman L et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer 2003; 4: 340-347.
48. Smith K, Fox SB, Whitehouse R et al. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol 1999; 10: 707-713.
49. Yiangou C, Gomm JJ, Coope RC et al. Fibroblast growth factor 2 in breast cancer: Occurrence and prognostic significance. Br J Cancer 1997; 75: 28-33.
50. Obermair A, Speiser P, Reisenberger K et al. Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett 1998; 130: 69-76.
51. Bredel M, Pollack IF, Campbell JW, Hamilton RL. Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas. Clin Cancer Res 1997; 3: 2157-2164.
52. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
53. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
54. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutabon and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
55. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2(3): E73.
56. Kopp R, Pfeiffer A. Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res 1990; 50: 6490-6496.
57. Fujiuchi S, Ohsaki Y, Kikuchi K. Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor. Oncology 1997; 54: 134-140.
58. Lokshin A, Peng X, Campbell PG et al. Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines. Cancer Chemother Pharmacol 1999; 43: 341-347.